Management of Psoriasis During Preconception, Pregnancy, Postpartum, and Breastfeeding: A Consensus Statement. / Consenso sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto y la lactancia en pacientes con psoriasis.

OBJECTIVE: To develop evidence- and experience-based recommendations for the management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding. METHODS: The nominal group technique and the Delphi method were used. Fifteen experts (12 dermatologists, 2 of whom were appointed coordinators; 1 rheumatologist; and 2 gynecologists) were selected to form an expert panel. Following a systematic review of the literature on fertility, pregnancy, postpartum, and breastfeeding in women with psoriasis, the coordinators drew up a series of preliminary recommendations for discussion by the panel at a nominal group meeting. The experts defined the scope, sections, and intended users of the statement and prepared a final list of recommendations. Consensus was obtained using a Delphi process in which an additional 51 dermatologists rated their level of agreement with each recommendation on a scale of 1 (total disagreement) to 10 (total agreement). Consensus was defined by a score of 7 or higher assigned by at least 70% of participants. Level of evidence and strength of recommendation were reported using the Oxford Center for Evidence-Based Medicine categories. The final statement was approved by the expert panel. RESULTS: The resulting consensus statement includes 23 recommendations on preconception (fertility and contraception), pregnancy (planning, pharmacological management, and follow-up), and breastfeeding (management and follow-up). Consensus was achieved for all recommendations generated except one. CONCLUSIONS: These recommendations for the better management of psoriasis in women of childbearing age could improve outcomes and prognosis.

Síndrome de Stevens-Johnson secundario a tratamiento con doxiciclina en un adolescente / Stevens-Johnson Syndrome Secondary to Doxycycline Treatment in a Teenage Boy

No disponible

Azatioprina en el tratamiento de la dermatitis atópica grave en pediatría. Experiencia en un hospital de referencia en España / Azathioprine in the Treatment of Severe Pediatric Atopic Dermatitis: Experience in a Referral Hospital in Spain

Antecedentes: La dermatitis atópica (DA) es una enfermedad inflamatoria crónica de la piel típicamente infantil cuyas formas graves pueden afectar intensamente la calidad de vida del paciente. Existen formas refractarias al tratamiento convencional en las que es preciso emplear inmunosupresores sistémicos como la azatioprina (AZA) para alcanzar un buen control de la enfermedad. Objetivo: Evaluar la eficacia y la tolerancia de la AZA en niños con DA grave. Pacientes y métodos: Se realizó una revisión retrospectiva de niños con DA grave tratados con AZA entre enero de 2007 y mayo de 2017. Resultados: Se revisaron 11 pacientes (6 varones, 5 mujeres) con una edad promedio de 13 años (rango 8-18 años). La edad media ± DE al inicio del tratamiento fue de 10,9 ± 2,2 años (IC 95% 8,6-13,1). La media de la dosis inicial de AZA fue de 1,8 ± 0,2 mg/kg/d. Evaluamos la respuesta al tratamiento de nuestros pacientes a las 4 semanas, entre la semana 12 y la 16, y a partir de los 6 meses. La media del tratamiento fue de 10,8 ± 5,7 meses. Dos pacientes tuvieron que suspender el tratamiento por efectos adversos. Siete de los 9 pacientes restantes presentaron un aclaramiento completo o casi completo de la DA a los 6 meses de tratamiento. Conclusión: En nuestra experiencia, la AZA es bien tolerada y puede ser considerada como una opción terapéutica en los niños con DA grave refractaria a tratamientos convencionales

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease that typically affects children. Severe forms may have a profound effect on patients’ quality of life. Some forms are resistant to conventional treatment and require the use of systemic immunosuppressants such as azathioprine (AZA) to adequately manage the disease. Objective: To evaluate the effectiveness and tolerance of AZA in children with severe AD. Patients and methods: We performed a retrospective study of children with severe AD treated with AZA between January 2007 and May 2017. Results: We reviewed the cases of 11 patients (6 boys and 5 girls) with a mean age of 13 years (range, 8-18 years). The mean (SD) age at start of treatment was 10.9 (2.2) years (95% CI 8.6-13.1). The mean initial dosage of AZA was 1.8 (0.2) mg/kg/d. We evaluated treatment response after 4 weeks, 12 to 16 weeks, and 6 months. Mean treatment duration was 10.8 (5.7) months. Treatment had to be suspended in 2 patients because of adverse effects. Seven of the 9 remaining patients presented complete or almost complete clearance of the AD after 6 months of treatment. Conclusion: In our experience, AZA is well tolerated and may be considered as a treatment option in children with severe AD resistant to conventional treatment

Algoritmo de tratamiento con omalizumab en urticaria crónica espontánea / Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab

Antecedentes y objetivo: Los ensayos pivotales de omalizumab en urticaria crónica espontánea (UCE) tienen un periodo de tratamiento de entre 12 y 24 semanas. Sin embargo, muchos pacientes en práctica clínica requieren periodos de tratamiento más prolongados. Por ello el objetivo es presentar un algoritmo de manejo del fármaco. Materiales y métodos: El documento de consenso que detallamos nace de la puesta en común, aceptación, revisión y confrontación de la literatura reciente del grupo de trabajo de UCE "Xarxa d'Urticària Catalana i Balear" (XUrCB). Resultados: Se inicia el tratamiento a dosis autorizada y se ajusta la dosis en intervalos trimestrales en función del Urticaria Activity Score de los últimos 7 días (UAS7) y/o el Urticarial Control Test (UCT). Conclusiones: El algoritmo propuesto pretende servir de guía respecto a cómo ajustar dosis, cómo y cuándo parar el fármaco y el modo de reintroducirlo en casos de recaída

Background and objective: Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many patients need longer treatment. In this article, we present an algorithm for treatment with omalizumab. Material and methods: The consensus document we present is the result of a series of meetings by the CSU working group of "Xarxa d'Urticària Catalana i Balear" (XUrCB) at which data from the recent literature were presented, discussed, compared, and agreed upon. Results: Treatment with omalizumab should be initiated at the authorized dose, and is adjusted at 3-monthly intervals according to the Urticaria Activity Score Over 7 days, the Urticaria Control Test, or both. Conclusions: The algorithm proposed is designed to provide guidance on how to adjust omalizumab doses, how and when to discontinue the drug, and how to reintroduce it in cases of relapse

Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab. / Algoritmo de tratamiento con omalizumab en urticaria crónica espontánea.

BACKGROUND AND OBJECTIVE: Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many patients need longer treatment. In this article, we present an algorithm for treatment with omalizumab. MATERIAL AND METHODS: The consensus document we present is the result of a series of meetings by the CSU working group of "Xarxa d'Urticària Catalana i Balear" (XUrCB) at which data from the recent literature were presented, discussed, compared, and agreed upon. RESULTS: Treatment with omalizumab should be initiated at the authorized dose, and is adjusted at 3-monthly intervals according to the Urticaria Activity Score Over 7days, the Urticaria Control Test, or both. CONCLUSIONS: The algorithm proposed is designed to provide guidance on how to adjust omalizumab doses, how and when to discontinue the drug, and how to reintroduce it in cases of relapse.

Reflectance confocal microscopy for the diagnosis of vulvar naevi: six cases.

BACKGROUND AND OBJECTIVES: The differential diagnosis between vulvar naevi and melanoma is challenging. In vivo reflectance-mode confocal microscopy (RCM) is an emerging technique that allows non-invasive high-resolution imaging of the skin and mucosa. It has recently been used for the study of vulvar melanosis and melanoma, but it has not been so far employed for the diagnosis of genital naevi. The objective of this study is to evaluate RCM features of vulvar naevi and to compare them with dermoscopical and histopathological aspects. METHODS: Clinical, dermoscopical, in vivo RCM and histological features of six vulvar naevi were evaluated. RESULTS: The clinical and/or dermoscopical aspects were suspicious in all six cases. RCM showed a blue naevus, an atypical genital naevus, a junctional naevus and three compound naevi that were later confirmed by histological examination. In one compound naevus, RCM showed focal cytological atypia and architectural irregularity without clear features of malignancy, confirmed by histological examination. CONCLUSIONS: Reflectance-mode confocal microscopy can play a role in non-invasive diagnosis of vulvar naevi, but further broader studies are required to validate our observations.

[The clinical spectrum of cutaneous neonatal lupus erythematosus]. / Espectro clínico del lupus eritematoso neonatal cutáneo.

BACKGROUND: Neonatal lupus erythematosus (NLE) is an uncommon disease described mainly through isolated case reports and a few published series. OBJECTIVE: To examine the clinical and serological spectrum, and course of the disease in neonates with NLE and cutaneous involvement. METHODS: A retrospective study was performed that included all children with NLE that came to the Dermatology Department between 1995 and 2006. RESULTS: Eight children with a diagnosis of NLE with cutaneous involvement were identified, with a male:female ratio of 3:1. Anti-Ro antibodies were found in all cases and no cases with anti-RNP antibodies were found. Facial lesions were observed in all cases and in 7 cases the skin eruptions cleared within 4.3 months; the remaining patient was still in follow up when the data were collected. The clinical course of patients who were followed up was satisfactory. CONCLUSIONS: In our series, NLE was three times more frequent in males. Involvement of sun-exposed areas, such as the face with annular lesions was the most common finding. We found one case of NLE with cutaneous involvement and persistent ductus arteriosus. Anti-Ro antibodies were found in all cases and skin eruptions cleared by 7 months of age, concurrent with the waning of the maternally derived antibodies. Four of the mothers were asymptomatic and unaware of their condition, emphasizing the importance of following up these patients due to the possibility of developing an autoimmune disease.

Espectro clínico del lupus eritematoso neonatal cutáneo / The clinical spectrum of cutaneous neonatal lupus erythematosus

Antecedentes: el lupus eritematoso neonatal (LEN) es una enfermedad poco frecuente descrita básicamente a través de casos aislados, con pocas series extensas publicadas. Objetivo: analizar las características clínicas, serológicas y el curso de la enfermedad en recién nacidos con LEN que consultaron por lesiones cutáneas. Métodos: se realizó un estudio retrospectivo, a partir de historias clínicas, de los niños con LEN que consultaron al servicio de dermatología en 1995–2006.Resultados: se estudió un total de 8 pacientes con una relación varón : mujer de 3:1. En todos los casos los niños presentaron anticuerpos anti-Ro y no se encontró ningún caso con anticuerpos anti-RNP. Las lesiones cutáneas afectaron a la cara en todos los casos y en 7 de los casos se resolvieron en una media de 4,3 meses; el caso restante continuaba en seguimiento cuando se recogieron los datos. La evolución de los pacientes en quienes se realizó seguimiento fue favorable. Conclusiones: en nuestra serie, el LEN ha sido 3 veces más frecuente en recién nacidos varones. La afectación de zonas fotoexpuestas, como la cara, con lesiones de morfología anular ha sido el hallazgo más frecuente. Hemos encontrado un caso de LEN con afectación cutánea y ductus arteriosus persistente. En todos los casos se han encontrado anticuerpos anti-Ro y las lesiones se han resuelto antes de los 7 meses de edad, coincidiendo con el aclaramiento de éstos. Debemos destacar que 4 de las madres estaban asintomáticas y desconocían su enfermedad y la importancia del seguimiento de estas pacientes ante el eventual desarrollo de una enfermedad autoinmunitaria (AU)

Background: Neonatal lupus erythematosus (NLE) is an uncommon disease described mainly through isolated case reports and a few published series. Objective: To examine the clinical and serological spectrum, and course of the disease in neonates with NLE and cutaneous involvement. Methods: A retrospective study was performed that included all children with NLE that came to the Dermatology Department between 1995 and 2006.Results: Eight children with a diagnosis of NLE with cutaneous involvement were identified, with a male : female ratio of 3:1. Anti-Ro antibodies were found in all cases and no cases with anti-RNP antibodies were found. Facial lesions were observed in all cases and in 7 cases the skin eruptions cleared within 4.3 months; the remaining patient was still in follow up when the data were collected. The clinical course of patients who were followed up was satisfactory. Conclusions: In our series, NLE was three times more frequent in males. Involvement of sun-exposed areas, such as the face with annular lesions was the most common finding. We found one case of NLE with cutaneous involvement and persistent ductus arteriosus. Anti-Ro antibodies were found in all cases and skin eruptions cleared by 7 months of age, concurrent with the waning of the maternally derived antibodies. Four of the mothers were asymptomatic and unaware of their condition, emphasizing the importance of following up these patients due to the possibility of developing an autoimmune disease (AU)

[Skin dimpling: a complication of amniocentesis]. / Hoyuelos cutáneos: una complicación de la amniocentesis.

Second trimester amniocentesis is widely used for the prenatal diagnosis of congenital disorders. Direct fetal injury from needle puncture can cause cutaneous scarring and rarely leads to severe visceral complications. Before the advent of real-time ultrasonography, the incidence of cutaneous lesions after amniocentesis ranged from 0.1 % to 9 % in the different series. Few reports of cutaneous lesions after amniocentesis have been published since the advent of real-time ultrasonography, although the real incidence is unknown. Eight children with typical skin dimpling caused by needle puncture during second trimester amniocentesis are presented. Current amniocentesis has not completely eliminated the risk of needle puncture scarring of the fetus. Dermatologists, pediatricians and obstetricians should be aware of this complication, which may have medical and legal consequences.

Hoyuelos cutáneos: una complicación de la amniocentesis / Skin dimpling: a complication of amniocentesis

La amniocentesis durante el segundo trimestre de gestación se realiza para el diagnóstico de alteraciones congénitas. La punción del feto durante la técnica puede conllevar lesiones cutáneas que raramente se acompañan de lesiones viscerales graves. Antes del uso de la ultrasonografía durante el procedimiento la incidencia de lesiones cutáneas variaba del 0,1 al 9 %. Con el uso de amniocentesis eco-guiada existen pocos casos publicados de lesiones cutáneas, si bien su incidencia no se conoce con exactitud. Presentamos 8 pacientes con hoyuelos cutáneos causados por la punción del feto durante amniocentesis del segundo trimestre de gestación. La amniocentesis actual (eco-dirigida) no ha eliminado completamente el riesgo de punción del feto durante la técnica. Dermatólogos, obstetras y pediatras deberán conocer esta complicación que puede conllevar consecuencias médico-legales

Second trimester amniocentesis is widely used for the prenatal diagnosis of congenital disorders. Direct fetal injury from needle puncture can cause cutaneous scarring and rarely leads to severe visceral complications. Before the advent of real-time ultrasonography, the incidence of cutaneous lesions after amniocentesis ranged from 0.1 % to 9 % in the different series. Few reports of cutaneous lesions after amniocentesis have been published since the advent of real-time ultrasonography, although the real incidence is unknown. Eight children with typical skin dimpling caused by needle puncture during second trimester amniocentesis are presented. Current amniocentesis has not completely eliminated the risk of needle puncture scarring of the fetus. Dermatologists, pediatricians and obstetricians should be aware of this complication, which may have medical and legal consequences

Incontinentia pigmenti: a report of ten cases.

A multidisciplinary approach is necessary in the care of patients with incontentia pigmenti (Bloch-Sulzberger syndrome).